Product Reports Resources Pricing Login Book a demo

Dermapharm

Biotech & Life Sciences · Grünwald, Germany · Founded 1991 · IPO 2018

Offers dermatological, skin care, and allergy medicines

Valuation $3.20B
Revenue $1.33B
EBITDA $376M

Talent graph

Dermapharm's talent

Book a demo to see the people
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Where Dermapharm has talent and traffic

Workforce by country
3 countries with
team presence
🇩🇪 Germany85.2%
🇨🇭 Switzerland13.1%
🇨🇳 China1.7%
3 countries shown

Patent intelligence

$20M patent portfolio · 21 active families

Estimated portfolio value
$20M
0.62% of market cap · 1.9× larger than top peer Kerecis ($11M)
21 active patent families
Where Dermapharm innovates Biomedical engineeringCatabolismDiseaseDisease injuryDrug

Where Dermapharm concentrates vs peers

Each axis is a top-10 topic across Dermapharm and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Dermapharm's 6 investments and acquisitions.

Every disclosed deal where Dermapharm appeared as a backer or acquirer, 2019–2023. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

6 deals across Dermapharm's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        Dermapharm's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        6 of 6 deals

        Market sentiment

        What the market is saying about Dermapharm

        An AI-synthesized read of the highest-engagement posts about Dermapharm on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Dermapharm on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.